The insider trading laws of the United States prohibit buying or selling a company’s securities while aware of material, non-public information about that company. It may also violate U.S. securities laws to disclose material, non-public information (deliberately or inadvertently) to another person (including a spouse, parent, child or sibling) if, as a result of the disclosure, that person either buys or sells securities while aware of the information disclosed, or passes that information to a third party who does. Providing advice regarding a company’s stock while aware of material non-public information regarding that company may also violate civil and criminal U. S. securities laws. If individuals subject to this policy make such a disclosure or provide such advice, individuals subject to this policy may be subject to damages, civil suits and criminal prosecution, regardless of whether individuals subject to this policy receive financial gain from the transaction.
Please refer to Amgen’s current Insider Trading Policy for additional details regarding the policy and the obligations of individuals subject to the policy. It is important to note that the restrictions in Amgen’s Insider Trading Policy apply to family members, not just to Amgen staff members, consultants, contract workers and temporary staff.
If individuals subject to this policy are aware of a situation that individuals subject to this policy believe may be a violation of Amgen’s Insider Trading Policy, individuals subject to this policy should immediately contact the Business Conduct Hotline (see "Reporting a Concern").
Please note that many other countries have similar laws regarding insider trading. Consequently, Amgen’s Insider Trading Policy applies to all Amgen staff members regardless of their location, even if the activities prohibited in the policy are not illegal in the country where the staff member is located.